Pfizer, which has clashed with President Trump over drug prices, has appointed former FDA commissioner Scott Gottlieb to its board of directors. The role pays $335,000 annually in cash and stock.
The big picture: Since leaving the Trump administration roughly 3 months ago, Gottlieb has rejoined a conservative think tank and a venture capital firm that has pharmaceutical investments. Cycling between public office and well-paying private sector companies has become commonplace among FDA officials as well as other top health agency leaders.
